Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.
Banner Image

All Things Covid-19: Therapies / Management / Treatment

Therapies / Articles

Article Title


Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial  JAMA 21-JAN-2021 Treatment with bamlanivimab and etesevimab combination therapy, but not bamlanivimab monotherapy, resulted in a reduction in SARS-CoV-2 log viral load at day 11 in patients with mild to moderate COVID-19.

Early high-titer plasma therapy to prevent severe COVID-19 in older adults.   

NEJM 06-JAN-2021

160 mild covid patients who received convalescent plasma within 72 hrs after onset of symptoms were 48% less likely to develop severe respiratory disease compared to patients receiving placebo.

Remdesivir for the Treatment of COVID-19 - Final Report NEJM 08-OCT-2020
Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants and cell protectives against SARS-C0V-2 papain-like protease Jnl Biomolec Struct & Dnamics  29-JUN-2020
Emergency use Authorization for Potential COVID-19 Treatment. [Remdesivir] U.S. FDA News Release 01-MAY-2020

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial 

The Lancet 29-APR-2020
Rationale for Consideration of Statins for COVID-19 Patients Massachusetts General
More on Chloroquine / Azithromycin.  And on Dr. Raoult.  By Derek Lowe Opinion / Commentary  Science Translational Medicine 29-MAR-2020

The use of anti-inflammatory drugs in the treatment of people with severe Coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China

Clinical Immunology Review.  May 2020

Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19

NEJM Special Report 30-MAR-2020

Updated approaches against SARS-CoV-2  

Antimicrob Agents & Chemo "mini-review"

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Int Jnl Antimicrob Agents Small sample size, adult patients,  promising results
TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib Jnl Microbiol Immunol Infect 

Therapies / Resources



Assessment of Evidence for COVID-19-Related Treatments American Society of Health System Pharmacists (ASHP) Look for "Evidence Table" on the webpage.
BLAZE-1 Clinical Trial 2 monoclonal antibodies showed evidence of efficacy. From a Eli Lilly Press Release 07-OCT-2020.   Not peer reviewed.
Tocilizumab: drug vignette University of  Oxford EBM center. updated 05-AUG-2020
Ad-Hoc COVID-19 Treatment Team algorithms & protocols.   Yale University; color coded guidance sheets, from "non-severe"  to severe disease. Updated as reliable information emerges. 03-AUG-2020
COVID-19 Treatment University of Washington.  Includes educational  info & slide decks on all aspects of treatment.
Fact sheet for health care providers: Emergency use authorization of Remdesivir (GS-5734™) FDA Fact Sheet 01-MAY-2020
Evidence Table of COVID-19-Related [Drug] Treatments. American Society of Health-System Pharmacists 04-MAY-2020
A real-time dashboard of clinical trials for COVID-19 The Lancet; 24-APR-2020 graphic of trials 

BMJ Best Practice "Approach"

Brit Med Jnl. Approach to therapy from severe to mild cases, comorbidities, pregnant women & neonates

BMJ Best Practice "Treatment Algorithm"

Brit Med Jnl.  Algorithms for suspected & confirmed COVID-19 infection

BMJ Best Practice "Emerging Treatments"

Brit Med Jnl. 

BMJ Best Practices Complications

Brit Med Jnl. Known complications, their likelihoods, and time frames

COVID-19 Drug Therapy - Potential Options

Pharmacist Summary - Elsevier
COVID-19 Antiviral and Pharmacotherapy Recommendations  U of Nebraska Medical Center Pharmacy Recommendations

Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics 

The Lancet Respiratory Medicine Provides an algorithm to follow